SEC Form 4 · accession 0000899243-17-000470
Dicerna Pharmaceuticals Inc · DRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Fambrough
Officer — Chief Executive Officer · Director
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001399529
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $2.97 | Jan 3, 2017 | A | 225,000 | A | — | Jan 3, 2027 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.